Fan Pengbei, Zhang Yige, Ding Shenao, Du Zhixin, Zhou Chunyu, Du Xiaodan
School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
The Second Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou, China.
Front Pharmacol. 2023 Mar 10;14:1139137. doi: 10.3389/fphar.2023.1139137. eCollection 2023.
Our study focused on whether macrophages ferroptosis is associated with the pathogenesis of chronic obstructive pulmonary disease (COPD) or not. We first identified macrophage module genes by weighted gene co-expression network analysis (WGCNA) in RNA sequencing (RNA-seq) date from COPD, and then identified macrophage marker genes by comprehensive analysis of single-cell RNA sequencing (scRNA-seq) data from COPD macrophages. There were 126 macrophage marker genes identified, and functional enrichment analyses indicated that ferroptosis pathway genes were significantly enriched. Secondly, we identified eight macrophage ferroptosis related genes and based on these eight genes, we performed co-expression analysis and drug prediction. Thirdly, two biomarkers (SOCS1 and HSPB1) were screened by the least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine-recursive feature elimination (SVM-RFE) and established an artificial neural network (ANN) for diagnosis. Subsequently, the biomarkers were validated in the dataset and validation set. These two biomarkers were then subjected to single gene-gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) analysis, and the ceRNA network was constructed. Finally, we carried out molecular validation with COPD models for cell counting kit-8 (CCK8) experiments, Western blot and quantitative real-time PCR (qRT-PCR) analysis and transmission electron microscopy (TEM). This study revealed the vital role of macrophage ferroptosis in COPD, and novel biomarkers (SOCS1 and HSPB1) may be involved in the pathogenesis of COPD by regulating macrophage ferroptosis. Taken together, our results suggest that targeting SOCS1 and HSPB1 could treat COPD by inhibiting macrophage ferroptosis.
我们的研究聚焦于巨噬细胞铁死亡是否与慢性阻塞性肺疾病(COPD)的发病机制相关。我们首先通过加权基因共表达网络分析(WGCNA)在慢性阻塞性肺疾病的RNA测序(RNA-seq)数据中鉴定巨噬细胞模块基因,然后通过对慢性阻塞性肺疾病巨噬细胞的单细胞RNA测序(scRNA-seq)数据进行综合分析来鉴定巨噬细胞标记基因。共鉴定出126个巨噬细胞标记基因,功能富集分析表明铁死亡途径基因显著富集。其次,我们鉴定了8个与巨噬细胞铁死亡相关的基因,并基于这8个基因进行了共表达分析和药物预测。第三,通过最小绝对收缩和选择算子(LASSO)、随机森林(RF)和支持向量机递归特征消除(SVM-RFE)筛选出两个生物标志物(SOCS1和HSPB1),并建立了用于诊断的人工神经网络(ANN)。随后,在数据集和验证集中对这些生物标志物进行了验证。然后对这两个生物标志物进行单基因-基因集富集分析(GSEA)和基因集变异分析(GSVA),并构建ceRNA网络。最后,我们用慢性阻塞性肺疾病模型进行了细胞计数试剂盒-8(CCK8)实验、蛋白质免疫印迹和定量实时PCR(qRT-PCR)分析以及透射电子显微镜(TEM)的分子验证。本研究揭示了巨噬细胞铁死亡在慢性阻塞性肺疾病中的重要作用,新的生物标志物(SOCS1和HSPB1)可能通过调节巨噬细胞铁死亡参与慢性阻塞性肺疾病的发病机制。综上所述,我们的结果表明,靶向SOCS1和HSPB1可能通过抑制巨噬细胞铁死亡来治疗慢性阻塞性肺疾病。